Drug profile · INN
pegvisomant
SOMAVERT
pegvisomant (SOMAVERT) is a growth hormone receptor antagonist. Associated with Pfizer Australia Pty Ltd. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — pegvisomant
- US status
- approved
- Class
- Systemic hormonal preparations (H01)
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
pegvisomant (SOMAVERT) is a growth hormone receptor antagonist. Associated with Pfizer Australia Pty Ltd. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Growth hormone receptor antagonist
Primary target: Growth hormone receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Related & competitor drugs
Frequently asked questions
What is pegvisomant?
pegvisomant (SOMAVERT) is a growth hormone receptor antagonist. Associated with Pfizer Australia Pty Ltd. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for pegvisomant?
SOMAVERT is a marketed brand name for pegvisomant. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of pegvisomant?
pegvisomant has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.